The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Tumor Necrosis Factor α As a New Target for Renal Cell Carcinoma: Two Sequential Phase II Trials of Infliximab at Standard and High Dose
Open accessAbstract
Purpose: Tumor necrosis factor α (TNF-α) may play a role in renal cell carcinoma (RCC). We performed two sequential phase II studies of infliximab, an anti–TNF-α monoclonal antibody, in patients with immunotherapy-resistant or refractory RCC. Patients and Methods: Patients progressing after cytokine therapy were treated with intravenous infliximab as follows: study 1 (19 patients), 5 mg/kg at weeks 0, 2, and 6, and then every 8 weeks; study 2 (18 patients), 10 mg/kg at weeks 0, 2, and 6, and then every 4 weeks. Treatment continued until disease progression (PD). Response was assessed according to Response Evaluation Criteria in Solid Tumors. Plasma levels of TNF-α, CCL2, and interleukin-6 (IL-6) were measured before and during treatment. Results: TNF-α and its receptors were detected in malignant cells in RCC biopsies. In study 1, three patients (16%) achieved partial response (PR) and three patients (16%) achieved stable disease (SD). Median duration of response (PR + SD) was 7.7 months (range, 5.0 to 40.5+ months). In study 2, 11 patients (61%) achieved SD. Median duration of response was 6.2 months (range, 3.5 to 24+ months). One patient developed grade 3 hypersensitivity and another died as a result of pulmonary infection/sepsis. Enzyme-linked immunosorbent assay analysis of plasma revealed that higher levels of TNF-α at baseline and higher levels of CCL2 during treatment were associated with PD. There were also correlations between higher levels of TNF-α, IL-6, and CCL2 and poor survival (< 12 months). Conclusion: This is the first direct clinical evidence suggesting that TNF-α may be a therapeutic target in RCC. Plasma levels of TNF-α, IL-6, and CCL2 may have predictive and prognostic significance.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
The TNF and TNF Receptor Superfamilies
Locksley, R. M., Killeen, N., & Lenardo, M. J. (2001) · Cell · doi:10.1016/s0092-8674(01)00237-9 · Cited by 3,650
Cancer and the chemokine network
Balkwill, F. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1388 · Cited by 2,343
Self-citationMice deficient in tumor necrosis factor-α are resistant to skin carcinogenesis
Moore, R. J., Owens, D. M., Stamp, G., Arnott, C., Burke, F., East, N., Holdsworth, H., Turner, L., Rollins, B., Pasparakis, M., et al. (1999) · Nature Medicine · doi:10.1038/10552 · Cited by 839
Self-citation
Cited by
Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008) · Nature · doi:10.1038/nature07205 · Cited by 11,399
Self-citationCancer-related inflammation, the seventh hallmark of cancer: links to genetic instability
Colotta, F., Allavena, P., Sica, A., Garlanda, C., & Mantovani, A. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp127 · Cited by 2,890
The tumor microenvironment and its role in promoting tumor growth
Whiteside, T. L. (2008) · Oncogene · doi:10.1038/onc.2008.271 · Cited by 2,376
Targeting NF-κB pathway for the therapy of diseases: mechanism and clinical study
Yu, H., Lin, L., Zhang, Z., Zhang, H., & Hu, H. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00312-6 · Cited by 2,135
Tumour necrosis factor and cancer
Balkwill, F. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2628 · Cited by 1,915
Self-citationInflammation and cancer: advances and new agents
Crusz, S. M., & Balkwill, F. R. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.105 · Cited by 1,184
Self-citationHarnessing cytokines and chemokines for cancer therapy
Propper, D. J., & Balkwill, F. R. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00588-9 · Cited by 989
Self-citationCytokine patterns in patients with cancer: a systematic review
Lippitz, B. E. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70582-x · Cited by 905
Tumor necrosis factor and cancer, buddies or foes?
Wang, X., & Lin, Y. (2008) · Acta Pharmacologica Sinica · doi:10.1111/j.1745-7254.2008.00889.x · Cited by 730
Exploration of the medical periodic table: towards new targets
Barry, N. P. E., & Sadler, P. J. (2013) · Chemical Communications · doi:10.1039/c3cc41143e · Cited by 717
De Monte, L., Reni, M., Tassi, E., Clavenna, D., Papa, I., Recalde, H., Braga, M., Di Carlo, V., Doglioni, C., & Protti, M. P. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20101876 · Cited by 695
Cancer-related inflammation: Common themes and therapeutic opportunities
Balkwill, F. R., & Mantovani, A. (2012) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2011.12.005 · Cited by 685
Self-citationCandido, J., & Hagemann, T. (2013) · Journal of Clinical Immunology · doi:10.1007/s10875-012-9847-0 · Cited by 653
Dougan, M., & Dranoff, G. (2009) · Annual Review of Immunology · doi:10.1146/annurev.immunol.021908.132544 · Cited by 607
Targeting the microenvironment in solid tumors
Belli, C., Trapani, D., Viale, G., D'Amico, P., Duso, B. A., Della Vigna, P., Orsi, F., & Curigliano, G. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2018.02.004 · Cited by 496
Prophylactic TNF blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy
Perez-Ruiz, E., Minute, L., Otano, I., Alvarez, M., Ochoa, M. C., Belsue, V., de Andrea, C., Rodriguez-Ruiz, M. E., Perez-Gracia, J. L., Marquez-Rodas, I., et al. (2019) · Nature · doi:10.1038/s41586-019-1162-y · Cited by 480
Wenzel, S. E., Barnes, P. J., Bleecker, E. R., Bousquet, J., Busse, W., Dahlén, S.-E., Holgate, S. T., Meyers, D. A., Rabe, K. F., Antczak, A., et al. (2009) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200809-1512oc · Cited by 460
The immunology of renal cell carcinoma
Díaz-Montero, C. M., Rini, B. I., & Finke, J. H. (2020) · Nature Reviews Nephrology · doi:10.1038/s41581-020-0316-3 · Cited by 442
Axelrad, J. E., Lichtiger, S., & Yajnik, V. (2016) · World Journal of Gastroenterology · doi:10.3748/wjg.v22.i20.4794 · Cited by 431
European Evidence-based Consensus: Inflammatory Bowel Disease and Malignancies
Annese, V., Beaugerie, L., Egan, L., Biancone, L., Bolling, C., Brandts, C., Dierickx, D., Dummer, R., Fiorino, G., Gornet, J. M., et al. (2015) · Journal of Crohn's and Colitis · doi:10.1093/ecco-jcc/jjv141 · Cited by 428
The chemokine system and cancer
Balkwill, F. R. (2012) · The Journal of Pathology · doi:10.1002/path.3029 · Cited by 412
Self-citationInterleukin-6 as a Therapeutic Target in Human Ovarian Cancer
Coward, J., Kulbe, H., Chakravarty, P., Leader, D., Vassileva, V., Leinster, D. A., Thompson, R., Schioppa, T., Nemeth, J., Vermeulen, J., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-0945 · Cited by 390
Self-citationTNF signaling drives myeloid-derived suppressor cell accumulation
Zhao, X., Rong, L., Zhao, X., Li, X., Liu, X., Deng, J., Wu, H., Xu, X., Erben, U., Wu, P., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci64115 · Cited by 378
Targeting cancer-promoting inflammation — have anti-inflammatory therapies come of age?
Hou, J., Karin, M., & Sun, B. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-00459-9 · Cited by 366
The tumor-promoting actions of TNF-α involve TNFR1 and IL-17 in ovarian cancer in mice and humans
Charles, K. A., Kulbe, H., Soper, R., Escorcio-Correia, M., Lawrence, T., Schultheis, A., Chakravarty, P., Thompson, R. G., Kollias, G., Smyth, J. F., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci39065 · Cited by 338
Self-citationCytokines as a key component of cancer-related inflammation
Germano, G., Allavena, P., & Mantovani, A. (2008) · Cytokine · doi:10.1016/j.cyto.2008.07.014 · Cited by 331
Jung, H.-Y., Fattet, L., & Yang, J. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-3173 · Cited by 309
Molecular mechanisms underlying chronic inflammation-associated cancers
Wu, Y., Antony, S., Meitzler, J. L., & Doroshow, J. H. (2014) · Cancer Letters · doi:10.1016/j.canlet.2013.08.014 · Cited by 308
The TNF Paradox in Cancer Progression and Immunotherapy
Montfort, A., Colacios, C., Levade, T., Andrieu-Abadie, N., Meyer, N., & Ségui, B. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01818 · Cited by 305
Cytokines, Inflammation and Colon Cancer
Klampfer, L. (2011) · Current Cancer Drug Targets · doi:10.2174/156800911795538066 · Cited by 289
Targeting the Tumor Microenvironment: From Understanding Pathways to Effective Clinical Trials
Fang, H., & DeClerck, Y. A. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-0661 · Cited by 284
Unleashing endogenous TNF-alpha as a cancer immunotherapeutic
Josephs, S. F., Ichim, T. E., Prince, S. M., Kesari, S., Marincola, F. M., Escobedo, A. R., & Jafri, A. (2018) · Journal of Translational Medicine · doi:10.1186/s12967-018-1611-7 · Cited by 257
Infliximab in the Treatment of Anti-CTLA4 Antibody (Ipilimumab) Induced Immune-Related Colitis
Minor, D. R., Chin, K., & Kashani-Sabet, M. (2009) · Cancer Biotherapy and Radiopharmaceuticals · doi:10.1089/cbr.2008.0607 · Cited by 120
Metadata
- Authors
- Harrison, M. L., Obermueller, E., Maisey, N. R., Hoare, S., Edmonds, K., Li, N. F., Chao, D., Hall, K., Lee, C., Timotheadou, E., Charles, K., Ahern, R., King, D. M., Eisen, T., Corringham, R., DeWitte, M., Balkwill, F., & Gore, M.
- Venue
- Journal of Clinical Oncology
- Published
- 2007-10-10
- Volume
- 25
- Issue
- 29
- Pages
- 4542-4549
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2113760021
- Cited by
- 251
- References
- 4
- FWCI
- 11.46
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.